• Home
  • Molecular risk stratification is independent of EGFR mutation status in identifying early stage non-squamous non-small cell lung cancer patients at risk for recurrence and likely to benefit from adjuvant chemotherapy.

Molecular risk stratification is independent of EGFR mutation status in identifying early stage non-squamous non-small cell lung cancer patients at risk for recurrence and likely to benefit from adjuvant chemotherapy.

Author List
Gavitt A. Woodard, Johannes R. Kratz, Greg Haro, Matthew A. Gubens, Collin M. Blakely, Kirk D. Jones, Michael J. Mann, David M. Jablons
Publication
Clinical lung cancer
Publication ID (Profile URL)
https://researcherprofiles.org/profile/225078088
Publication Year
2021
Publication Title
Gavitt A. Woodard, Johannes R. Kratz, Greg Haro, Matthew A. Gubens, Collin M. Blakely, Kirk D. Jones, Michael J. Mann, David M. Jablons. Molecular risk stratification is independent of EGFR mutation status in identifying early stage non-squamous non-small cell lung cancer patients at risk for recurrence and likely to benefit from adjuvant chemotherapy. Clinical Lung Cancer. 2021 Aug 1.